Dysmorphic megakaryocytes in TAFRO syndrome: A case series from a single institute

Blood Cells, Molecules, and Diseases 108 巻 102870- 頁 2024-06-08 発行
アクセス数 : 3
ダウンロード数 : 0

今月のアクセス数 : 3
今月のダウンロード数 : 0
ファイル情報(添付)
利用開始日 2025-06-08 69.7 MB 種類 : 全文 エンバーゴ : 2025-06-08
タイトル ( eng )
Dysmorphic megakaryocytes in TAFRO syndrome: A case series from a single institute
作成者
Maida Shohei
Nakagawa Hiromi
Kajihara Kyoko
Yamazaki Shinichi
収録物名
Blood Cells, Molecules, and Diseases
108
開始ページ 102870
抄録
TAFRO syndrome is a rare systemic inflammatory disorder of unknown etiology characterized by thrombocytopenia, anasarca, fever, reticulin myelofibrosis, renal dysfunction, and organomegaly. The diagnosis of TAFRO syndrome can be challenging; however, prompt diagnosis is vital because TAFRO syndrome is a progressive and life-threatening disease. We have showcased five patients with TAFRO syndrome who had similar bone marrow (BM) findings that could be considered the findings that characterize TAFRO syndrome. All patients were treated with corticosteroids and tocilizumab; three of the five patients (60 %) responded positively to the treatment. The unique BM findings observed in this study were megakaryocytes with distinct multinuclei and three-dimensional and indistinct bizarre nuclei (“dysmorphic megakaryocyte”), similar to the megakaryocyte morphology observed in myeloproliferative neoplasms (MPNs). Notably, dysmorphic megakaryocytes were observed in all five cases, whereas only two of the five patients tested positive for reticulin myelofibrosis, and three of the five patients had megakaryocytic hyperplasia, which are considered typical findings of TAFRO syndrome. Thus, the BM findings of dysmorphic megakaryocytes could help in the correct and immediate diagnosis of TAFRO syndrome.
著者キーワード
TAFRO syndrome
Bone marrow aspirate
Dysmorphic megakaryocytes
Megakaryocytes with bizarre nuclei
Tocilizumab
内容記述
This work was supported in part by the Program of the Network-type Joint Usage/Research Center for Radiation Disaster Medical Science of Hiroshima University, Nagasaki University, and Fukushima Medical University (to TI).
言語
英語
資源タイプ 学術雑誌論文
出版者
Elsevier
発行日 2024-06-08
権利情報
© 2024. This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/
This is not the published version. Please cite only the published version.
この論文は出版社版ではありません。引用の際には出版社版をご確認、ご利用ください。
出版タイプ Accepted Manuscript(出版雑誌の一論文として受付されたもの。内容とレイアウトは出版社の投稿様式に沿ったもの)
アクセス権 エンバーゴ期間中
収録物識別子
[DOI] https://doi.org/10.1016/j.bcmd.2024.102870 ~の異版である
備考 The full-text file will be made open to the public on 8 June 2025 in accordance with publisher's 'Terms and Conditions for Self-Archiving'